Tin tức & Cập nhật

Effective treatment with pre-exposure prophylaxis (PrEP) for HIV puts a cap on the additional cost patients should be willing to pay for long-acting injectable cabotegravir (CAB-LA), reports a US study.

In patients with chronic spontaneous urticaria (CSU) who remained symptomatic despite treatment, the monoclonal anti-immunoglobulin E antibody ligelizumab improved symptom control regardless of BHRA* status, as well as dermatology quality of life (QoL) regardless of angioedema status, findings from a phase IIb study have shown.

In patients with gout and concurrent chronic kidney disease (CKD), the risk of mortality does not seem to increase with initiation of allopurinol, achieving target serum urate (SU) level with allopurinol, or treatment dose escalation, a study has shown.

Treatment with nonvitamin K antagonist oral anticoagulants (NOACs) results in lower risks of diabetes complications and mortality compared with warfarin in patients with atrial fibrillation (AF) and diabetes mellitus (DM), suggest a study.

In the phase II TITAN-TCC* trial presented at ASCO GU 2022, the addition of ipilimumab to nivolumab led to improved responses in patients with pretreated (second/third line) advanced/metastatic or surgically unresectable transitional cell carcinoma (TCC).

Combining pembrolizumab with best supportive care (BSC) improved survival and response when used as second-line therapy in Asians with advanced hepatocellular carcinoma (HCC).

The early addition of ivermectin to standard of care (SoC)* in high-risk patients with mild-to-moderate COVID-19 did not prevent progression to severe disease compared with SoC alone, according to results of the I-TECH** trial conducted in Malaysia.